

StrideSM (HMO)/(HMO-POS) Medicare Advantage Network Operations

Cell and Gene Therapy (CGT) Monitoring

Description

Cell and gene therapy offer significant advances to patients with a transformative approach to improve function and fight disease. While inspiring innovations in care, they are very costly with uncertainties in the long-term clinical benefits and the value they bring to a patient's overall healthcare needs. For more information, view our medical necessity guidelines for more information on cell and gene therapy drugs.

Policy

To ensure efficacy and durability of response, high-cost therapies are subject to long-term monitoring. Providers must comply with long-term monitoring requirements including requests for follow-up clinical data and/or attestation of clinical outcome.

PUBLICATION HISTORY 08/01/23 original documentation